- Home
- OSS vs CUE Comparison
OSS vs CUE Comparison
Compare OSS & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OSS
- CUE
- Stock Information
- Founded
- OSS 1998
- CUE 2014
- Country
- OSS United States
- CUE United States
- Employees
- OSS N/A
- CUE N/A
- Industry
- OSS Computer Manufacturing
- CUE Biotechnology: Pharmaceutical Preparations
- Sector
- OSS Technology
- CUE Health Care
- Exchange
- OSS Nasdaq
- CUE Nasdaq
- Market Cap
- OSS 79.8M
- CUE 91.9M
- IPO Year
- OSS 2018
- CUE 2018
- Fundamental
- Price
- OSS $4.28
- CUE $1.44
- Analyst Decision
- OSS Strong Buy
- CUE Strong Buy
- Analyst Count
- OSS 2
- CUE 5
- Target Price
- OSS $5.25
- CUE $5.00
- AVG Volume (30 Days)
- OSS 214.5K
- CUE 396.9K
- Earning Date
- OSS 03-20-2025
- CUE 03-10-2025
- Dividend Yield
- OSS N/A
- CUE N/A
- EPS Growth
- OSS N/A
- CUE N/A
- EPS
- OSS N/A
- CUE N/A
- Revenue
- OSS $52,709,421.00
- CUE $9,532,000.00
- Revenue This Year
- OSS N/A
- CUE $73.11
- Revenue Next Year
- OSS $9.40
- CUE $11.02
- P/E Ratio
- OSS N/A
- CUE N/A
- Revenue Growth
- OSS N/A
- CUE 149.53
- 52 Week Low
- OSS $1.82
- CUE $0.45
- 52 Week High
- OSS $4.58
- CUE $2.58
- Technical
- Relative Strength Index (RSI)
- OSS 57.48
- CUE 54.92
- Support Level
- OSS $3.36
- CUE $1.27
- Resistance Level
- OSS $3.77
- CUE $1.45
- Average True Range (ATR)
- OSS 0.34
- CUE 0.13
- MACD
- OSS -0.04
- CUE 0.00
- Stochastic Oscillator
- OSS 56.06
- CUE 77.86
About OSS One Stop Systems Inc.
One Stop Systems Inc designs, manufactures, and markets specialized rugged high-performance compute ("HPC"), high-speed switch fabrics, and storage systems, which are designed to target edge applications for artificial intelligence ("AI") / machine learning ("ML"), sensor processing, sensor fusion, and autonomy. The company operates in two reportable segments; OSS designs and manufactures high-performance customized computers and flash arrays, in-flight entertainment & connectivity. Bressner operates as a system integrator with standard and custom all-in-one hardware systems and components for many kinds of industrial environments. The company generates the majority of its revenue from the Bresssner segment.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.